Patents Assigned to BioNTech AG
-
Patent number: 10980875Abstract: The present invention relates to particles comprising RNA, in which the RNA is associated with a cationic polymer or lipid or with both a cationic polymer and lipid, wherein the RNA comprises a cytotoxic nucleotide or cytotoxic nucleotide analog and/or the RNA is covalently attached to a cytotoxin, pharmaceutical compositions containing said particles and pharmaceutical uses of the particles and pharmaceutical compositions. The particles of the present invention are particularly useful as an immunostimulating medicament capable to block proliferation or induce death in dividing cells such as tumor cells.Type: GrantFiled: October 20, 2016Date of Patent: April 20, 2021Assignee: BIONTECH AGInventor: Steve Pascolo
-
Patent number: 10717780Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.Type: GrantFiled: August 30, 2018Date of Patent: July 21, 2020Assignees: BioNTech AG, Ganymed Pharmaceuticals GmbH, TRON—Translationale Onkologic an der Universitätsmedzin der Johannes Gutenberg-Universität Mainz gemcinnützige GmbHInventors: Ugur Sahin, Ozlem Türeci, Christiane Stadler, Julia Holland, Hayat Bähr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
-
Patent number: 10626400Abstract: The present invention relates to stable low-salt aqueous formulations of particles comprising a polycation, preferably protamine, and RNA, which formulations are preferably isotonic, to pharmaceutical compositions or kits comprising such formulations and to their use in medicine. It further relates to methods for preparing the formulations of the invention and to methods for physically stabilizing particles comprising a polycation, preferably protamine, and RNA.Type: GrantFiled: July 4, 2014Date of Patent: April 21, 2020Assignee: BioNTech AGInventor: Steve Pascolo
-
Patent number: 10370433Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.Type: GrantFiled: March 15, 2016Date of Patent: August 6, 2019Assignee: Biontech AGInventors: Ugur Sahin, Joycelyn Wüstehube-Lausch, Markus Fiedler, Matin Daneschdar, Hans-Ulrich Schmoldt
-
Patent number: 10302647Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.Type: GrantFiled: March 7, 2016Date of Patent: May 28, 2019Assignee: BIONTECH AGInventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
-
Patent number: 10253373Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.Type: GrantFiled: May 10, 2017Date of Patent: April 9, 2019Assignee: BIONTECH AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Publication number: 20190062762Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.Type: ApplicationFiled: September 27, 2018Publication date: February 28, 2019Applicant: BioNTech AGInventors: Ugur Sahin, Silke Holtkamp, Ozlem Tureci, Sebastian Kreiter
-
Patent number: 10188712Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.Type: GrantFiled: July 30, 2014Date of Patent: January 29, 2019Assignees: BIONTECH AG, TRON—Translationale Onkologie an der Universitätsmedizin Mainz Gemeinnützige GmbHInventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
-
Patent number: 10172960Abstract: The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation.Type: GrantFiled: March 21, 2017Date of Patent: January 8, 2019Assignee: BIONTECH AGInventor: Steve Pascolo
-
Patent number: 10106800Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.Type: GrantFiled: July 22, 2016Date of Patent: October 23, 2018Assignee: BioNTech AGInventors: Ugur Sahin, Silke Holtkamp, Ozlem Tureci, Sebastian Kreiter
-
Patent number: 10093736Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.Type: GrantFiled: November 12, 2013Date of Patent: October 9, 2018Assignees: BIONTECH AG, TRON GGMBH, UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AGInventors: Ugur Sahin, Ozlem Tureci, Christiane Stadler, Julia Holland, Hayat Bahr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
-
Publication number: 20180177885Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.Type: ApplicationFiled: February 13, 2018Publication date: June 28, 2018Applicant: BioNTech AGInventors: Ozlem Tureci, Ugur Sahin, Sebastian Kreiter
-
Publication number: 20180169236Abstract: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.Type: ApplicationFiled: August 11, 2017Publication date: June 21, 2018Applicant: BioNTech AGInventors: Ozlem Tureci, Ugur Sahin, Sandra Schneider, Gerd Helftenbein, Volker Schluter, Dirk Usener, Philippe Thiel, Michael Koslowski
-
Patent number: 9944708Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.Type: GrantFiled: November 25, 2014Date of Patent: April 17, 2018Assignee: BioNTech AGInventors: Klaus Pfizenmaier, Harald Wajant, Dieter Moosmayer, Thomas Wuest
-
Patent number: 9910043Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.Type: GrantFiled: February 18, 2016Date of Patent: March 6, 2018Assignee: BioNTech AGInventors: Özlem Türeci, Ugur Sahin, Gerd Helftenbein, Volker Schlüter
-
Patent number: 9730976Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.Type: GrantFiled: March 16, 2016Date of Patent: August 15, 2017Assignee: BioNTech AGInventors: Pierfausto Seneci, Laura Belvisi, Federica Cossu, Domenico Delia, Carmelo Drago, Daniele Lecis, Stefano Maiorana, Leonardo Pierpaolo Manzoni, Eloise Mastrangelo, Mario Milani de Mayo de Mari, Paola Maria Chiara Perego, Francesca Vasile
-
Patent number: 9637794Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.Type: GrantFiled: March 12, 2013Date of Patent: May 2, 2017Assignee: BIONTECH AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Patent number: 9636414Abstract: The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation.Type: GrantFiled: December 15, 2011Date of Patent: May 2, 2017Assignee: BIONTECH AGInventor: Steve Pascolo
-
Patent number: 9617321Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.Type: GrantFiled: August 12, 2014Date of Patent: April 11, 2017Assignees: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, BIONTECH AGInventors: Thorsten Klamp, Ugur Sahin, Ozlem Tureci, Michael Koslowski, Thomas Hiller, Jens Schumacher
-
Patent number: 9533043Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.Type: GrantFiled: September 25, 2013Date of Patent: January 3, 2017Assignee: BioNTech AGInventors: Özlem Türeci, Ugur Sahin, Sandra Schneider, Gerd Helftenbein, Volker Schlüter, Dirk Usener, Philippe Thiel, Michael Koslowski